TranS1’s mission is to craft world class products that solve spinal pathologies leading to excellent patient outcomes with minimal tissue trauma. With over 14,000 AxiaLIF® procedures performed in the US, and presently 90 peer-reviewed publications establishing the safety, efficacy and biomechanics of AxiaLIF®, there is ample reason to explore AxiaLIF® as a standard fusion procedure with an alternate approach.
The AxiaLIF® Plus (Axial Lumbar Interbody Fusion) System is designed to create a safe and reproducible anterior retroperitoneal pre-sacral access route to the L5-S1 vertebral bodies.
The featured instrumentation is designed to enable standard of care fusion principles, distraction, and stabilization of the anterior lumbar column, while mitigating the soft tissue trauma associated with traditional lumbar fusion.
Every step of the AxiaLIF® Plus procedure – Access, Discectomy, Grafting, Distraction, and Stabilization – is designed to produce quality patient outcomes including excellent fusion rates and low complication rates with procedural efficiencies in mind.
With over 14,000 AxiaLIF® procedures performed in the US, there are presently 90 peer-reviewed publications establishing the safety, efficacy and biomechanics of AxiaLIF®. Recognizing that each patient’s needs are unique, the AxiaLIF® Plus System represents an outstanding option to address pathology at L5-S1.
Meet patent attorney Jeff Schell. After successful exits from TranS1 and Rocky Mountain Patent, h...
